Regeneron Investor Interest

Order byBest matchMost fresh

Regeneron to buy bankrupt DNA testing company 23andMe

Regeneron agrees to buy bankrupt 23andMe, promises ethical use of customers' DNA data

Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of customers' DNA data.

· 1d · on MSN

· 1d

Regeneron agrees to buy bankrupt 23andMe

· 1d

Biotech company Regeneron to buy bankrupt 23andMe for $256M

23andMe to Be Bought by Biotech Company for $256 Million

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services.

· 22h

· 23h

23andMe Sold To Biotechnology Company For $256 Million

· 1d

Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million

A drug developer is buying 23andMe - what does that mean for your DNA data?

Regeneron vows to prioritize the privacy, security, and ethical use of customer data.

· 1d

23andMe bought by Regeneron in court auction

· 1d

Biotechnology Company Regeneron to Buy 23andMe for $256 million

1don MSN

Regeneron Pharmaceuticals to buy 23andMe for $256M

Regeneron Pharmaceuticals on Monday said it would buy genetic testing company 23andMe, which filed for bankruptcy in March following a series of setbacks.

Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% rise in 3 years.

23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.

Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles including a data breach.

Yahoo Finance20d

Q1 2025 Regeneron Pharmaceuticals Inc Earnings Call

Thank you for your interest in Regeneron and welcome to our first quarter 2025 earnings conference call. An archive and transcript of this call will be available on Regeneron's Investor Relations ...

Morningstar29d

Regeneron Announces Investor Conference Presentations

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and ...

STAT4d

Amgen loses $400 million antitrust battle to Regeneron

Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more.

Fintel on MSN5d

Citigroup Upgrades Regeneron Pharmaceuticals (REGN)

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Neutral to Buy. Analyst Price Forecast Suggests 44.26% Upside As of May 6, 2025,

4don MSN

Regeneron wins over $400M jury award as Amgen found liable in antitrust case

Regeneron (REGN) wins $400M in damages as jury finds Amgen (AMGN) violated antitrust laws by promoting its heart drug Repatha over rival's Praluent. Read more here.